This is a knockout-validated antibody summary, based on four publications "Tumor-intrinsic PIK3CA represses tumor immunogenecity in a model of pancreatic cancer" [4] (western blot, Figure s1a in the article), "A PI3K p110β-Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis" (Figure 1) [1], "Rac1-mediated membrane raft localization of PI3K/p110β is required for its activation by GPCRs or PTEN loss" (Figure 2) [2], and "The Effector TepP Mediates Recruitment and Activation of Phosphoinositide 3-Kinase on Early Chlamydia trachomatis Vacuoles" (Figure 3) [3]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Rabbit monoclonal
Company: Cell Signaling Technology
Antibody: PI3K p110α
Catalog number: 4249
Summary: Rabbit monoclonal antibody raised against a peptide corresponding to residues surrounding Asp520 of human p110α.
Supplier recommended for WB, IP and IHC.
Reacts with human, mouse, rat and cow p110α.
Western blot (Figure 1).

Lysates of spleen from wild-type and PI3K p110α -/- mice.
TBS containing 5% milk powder.
Anti-p110α antibody diluted 1:1000.
LI-COR 800 conjugated anti-rabbit IgG.
Odyssey detection system (LI-COR).

Western blot (Figure 2).
Wt, p110α,β-KO (DKO), DKO+p110α-wt and DKO+p110β-wt MEFs.
5% non-fat milk (LabScientific, Highlands, New Jersey) in TBS for 30 min.
Diluted in TBS containing 5% milk and 0.1% Tween-20 overnight at 4°C.
IRDye 800CW goat anti-rabbit secondary antibodies (Li-Cor, Lincoln, Nebraska) diluted in 5% milk-TBS for 1.5 hr at RT.
Odyssey CLx Scanner.
- If you are aware of any publication with knockout studies validating a monoclonal or recombinant antibody, either purchased from a supplier or developed by the author(s), please notify us through feedback.